Seroatlas · Human Serome Atlas

MAP1B

Microtubule-associated protein 1B

Also known as: MAP1B_HUMAN, MAP5, PPP1R102

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P46821
Gene
MAP1B
Ensembl
ENSG00000131711
Chromosome
5
Canonical length
2468 aa
Protein class
Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins
Subcellular location
Cytosol,Equatorial segment

OverviewNCBI Gene

This gene encodes a protein that belongs to the microtubule-associated protein family. The proteins of this family are thought to be involved in microtubule assembly, which is an essential step in neurogenesis. The product of this gene is a precursor polypeptide that presumably undergoes proteolytic processing to generate the final MAP1B heavy chain and LC1 light chain. Gene knockout studies of the mouse microtubule-associated protein 1B gene suggested an important role in development and function of the nervous system. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

2468 residues, UniProt reviewed canonical sequence.

>P46821|MAP1B
     1  MATVVVEATE PEPSGSIANP AASTSPSLSH RFLDSKFYLL VVVGEIVTEE HLRRAIGNIE
    61  LGIRSWDTNL IECNLDQELK LFVSRHSARF SPEVPGQKIL HHRSDVLETV VLINPSDEAV
   121  STEVRLMITD AARHKLLVLT GQCFENTGEL ILQSGSFSFQ NFIEIFTDQE IGELLSTTHP
   181  ANKASLTLFC PEEGDWKNSN LDRHNLQDFI NIKLNSASIL PEMEGLSEFT EYLSESVEVP
   241  SPFDILEPPT SGGFLKLSKP CCYIFPGGRG DSALFAVNGF NMLINGGSER KSCFWKLIRH
   301  LDRVDSILLT HIGDDNLPGI NSMLQRKIAE LEEEQSQGST TNSDWMKNLI SPDLGVVFLN
   361  VPENLKNPEP NIKMKRSIEE ACFTLQYLNK LSMKPEPLFR SVGNTIDPVI LFQKMGVGKL
   421  EMYVLNPVKS SKEMQYFMQQ WTGTNKDKAE FILPNGQEVD LPISYLTSVS SLIVWHPANP
   481  AEKIIRVLFP GNSTQYNILE GLEKLKHLDF LKQPLATQKD LTGQVPTPVV KQTKLKQRAD
   541  SRESLKPAAK PLPSKSVRKE SKEETPEVTK VNHVEKPPKV ESKEKVMVKK DKPIKTETKP
   601  SVTEKEVPSK EEPSPVKAEV AEKQATDVKP KAAKEKTVKK ETKVKPEDKK EEKEKPKKEV
   661  AKKEDKTPIK KEEKPKKEEV KKEVKKEIKK EEKKEPKKEV KKETPPKEVK KEVKKEEKKE
   721  VKKEEKEPKK EIKKLPKDAK KSSTPLSEAK KPAALKPKVP KKEESVKKDS VAAGKPKEKG
   781  KIKVIKKEGK AAEAVAAAVG TGATTAAVMA AAGIAAIGPA KELEAERSLM SSPEDLTKDF
   841  EELKAEEVDV TKDIKPQLEL IEDEEKLKET EPVEAYVIQK EREVTKGPAE SPDEGITTTE
   901  GEGECEQTPE ELEPVEKQGV DDIEKFEDEG AGFEESSETG DYEEKAETEE AEEPEEDGEE
   961  HVCVSASKHS PTEDEESAKA EADAYIREKR ESVASGDDRA EEDMDEAIEK GEAEQSEEEA
  1021  DEEDKAEDAR EEEYEPEKME AEDYVMAVVD KAAEAGGAEE QYGFLTTPTK QLGAQSPGRE
  1081  PASSIHDETL PGGSESEATA SDEENREDQP EEFTATSGYT QSTIEISSEP TPMDEMSTPR
  1141  DVMSDETNNE ETESPSQEFV NITKYESSLY SQEYSKPADV TPLNGFSEGS KTDATDGKDY
  1201  NASASTISPP SSMEEDKFSR SALRDAYCSE VKASTTLDIK DSISAVSSEK VSPSKSPSLS
  1261  PSPPSPLEKT PLGERSVNFS LTPNEIKVSA EAEVAPVSPE VTQEVVEEHC ASPEDKTLEV
  1321  VSPSQSVTGS AGHTPYYQSP TDEKSSHLPT EVIEKPPAVP VSFEFSDAKD ENERASVSPM
  1381  DEPVPDSESP IEKVLSPLRS PPLIGSESAY ESFLSADDKA SGRGAESPFE EKSGKQGSPD
  1441  QVSPVSEMTS TSLYQDKQEG KSTDFAPIKE DFGQEKKTDD VEAMSSQPAL ALDERKLGDV
  1501  SPTQIDVSQF GSFKEDTKMS ISEGTVSDKS ATPVDEGVAE DTYSHMEGVA SVSTASVATS
  1561  SFPEPTTDDV SPSLHAEVGS PHSTEVDDSL SVSVVQTPTT FQETEMSPSK EECPRPMSIS
  1621  PPDFSPKTAK SRTPVQDHRS EQSSMSIEFG QESPEQSLAM DFSRQSPDHP TVGAGVLHIT
  1681  ENGPTEVDYS PSDMQDSSLS HKIPPMEEPS YTQDNDLSEL ISVSQVEASP STSSAHTPSQ
  1741  IASPLQEDTL SDVAPPRDMS LYASLTSEKV QSLEGEKLSP KSDISPLTPR ESSPLYSPTF
  1801  SDSTSAVKEK TATCHSSSSP PIDAASAEPY GFRASVLFDT MQHHLALNRD LSTPGLEKDS
  1861  GGKTPGDFSY AYQKPEETTR SPDEEDYDYE SYEKTTRTSD VGGYYYEKIE RTTKSPSDSG
  1921  YSYETIGKTT KTPEDGDYSY EIIEKTTRTP EEGGYSYDIS EKTTSPPEVS GYSYEKTERS
  1981  RRLLDDISNG YDDSEDGGHT LGDPSYSYET TEKITSFPES EGYSYETSTK TTRTPDTSTY
  2041  CYETAEKITR TPQASTYSYE TSDLCYTAEK KSPSEARQDV DLCLVSSCEY KHPKTELSPS
  2101  FINPNPLEWF ASEEPTEESE KPLTQSGGAP PPPGGKQQGR QCDETPPTSV SESAPSQTDS
  2161  DVPPETEECP SITADANIDS EDESETIPTD KTVTYKHMDP PPAPVQDRSP SPRHPDVSMV
  2221  DPEALAIEQN LGKALKKDLK EKTKTKKPGT KTKSSSPVKK SDGKSKPLAA SPKPAGLKES
  2281  SDKVSRVASP KKKESVEKAA KPTTTPEVKA ARGEEKDKET KNAANASASK SAKTATAGPG
  2341  TTKTTKSSAV PPGLPVYLDL CYIPNHSNSK NVDVEFFKRV RSSYYVVSGN DPAAEEPSRA
  2401  VLDALLEGKA QWGSNMQVTL IPTHDSEVMR EWYQETHEKQ QDLNIMVLAS SSTVVMQDES
  2461  FPACKIEL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against MAP1B can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.56
Highest tissue expression
144 nTPM

Expression across tissuesHPA

Tissue

  • retina: 144 nTPM
  • cerebellum: 117 nTPM
  • spinal cord: 117 nTPM
  • cerebral cortex: 110 nTPM
  • midbrain: 94 nTPM
  • hypothalamus: 89 nTPM

Single-cell type

  • retinal ganglion cells: 838 nCPM
  • cone photoreceptor cells: 814 nCPM
  • pericytes: 771 nCPM
  • other brain neurons: 747 nCPM
  • brain excitatory neurons: 735 nCPM
  • pituicytes/fscs: 728 nCPM

Immune cell

  • total PBMC: 0.2 nTPM
  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM

Brain region

  • pons: 1,349 nTPM
  • medulla oblongata: 1,251 nTPM
  • thalamus: 1,118 nTPM
  • hypothalamus: 1,084 nTPM
  • midbrain: 1,058 nTPM
  • cerebral cortex: 1,024 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about MAP1B.

Disease | AllUniProt

Conditions MAP1B is implicated in, by any mechanism.

Disease | GeneticClinVar

43 pathogenic / likely-pathogenic of 651 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

ReferencesPubMed · IEDB

Publications for MAP1B from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

2 publications

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.13
gnomAD pLI
1
gnomAD missense Z
2.51
DepMap mean gene effect
-0.02
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of MAP1B in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads MAP1B as an antibody target. Whether an autoantibody or antibody against MAP1B could matter depends on whether native MAP1B is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

MAP1B is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label MAP1B as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/MAP1B. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...